NASDAQ · Biotechnology

NeuroSense Therapeutics Ltd. (NRSN) Stock

$0.60 -0.35% NASDAQ: NRSN Healthcare

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions.

Valuation

MetricValue
Price$0.60
Market Cap$21.21M
P/E Ratio-1.35
P/B Ratio-9.87
P/S Ratio0.00
EPS (TTM)$-0.44
52-Week High$2.09
52-Week Low$0.58
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE543.76%
ROA-458.07%
ROCE744.96%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.11
Current Ratio0.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-6.0M$-14.0M$-12.0M$-10.0M$-11.0M
Net Profit$-4.0M$-12.0M$-10.0M$-10.0M$-11.0M
EPS$-0.23$-1.07$-0.83$-0.55$-0.44
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$11.0M$8.0M$3.0M$5.0M$1.0M
Total Liabilities$2.0M$2.0M$5.0M$2.0M$3.0M
Cash$11.0M$4.0M$3.0M$3.0M$0
Borrowings$0$0$0$0$0

Latest News

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PR Newswire · Jul 6, 2026 NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint MT Newswires · Jun 29, 2026 NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS PR Newswire · Jun 29, 2026 NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease PR Newswire · Jun 25, 2026 EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots PR Newswire · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-8.0M$-8.0M$-10.0M$-8.0M
Investing Cash Flow$0$-4.0M$3.0M$0$0
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$10.0M$-8.0M$-1.0M$1.0M$-3.0M
Free Cash Flow$-2.0M$-8.0M$-8.0M$-10.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.99
EV / EBITDA-1.87
FCF Yield-37.72%
Quick Ratio0.33
Interest Coverage-652.06
Return 1Y-63.69%
Return 3Y-47.14%
Return 5Y—

Ownership

Insiders Held32.31%
Institutions Held1.07%
Institutions Float Held1.59%
Institutional HolderSharesReport Date
Yorkville Advisors Global, LP78,0002026-03-31
UBS Group AG49,0962026-03-31
Independent Advisor Alliance50,0002026-03-31
Two Sigma Investments, LP44,4452026-03-31
Meitav Investment House Ltd.40,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLGN $0.27 -9.04% -0.48 $3.54M 0.00%
CVKD $2.06 +0.98% -0.78 $6.38M 0.00%
ENLV $2.12 -5.36% 0.03 $35.68M 0.00%
KLTOKlotho Neurosciences, Inc. $0.38 -7.10% -1.13 $20.08M 0.00%
NERVMinerva Neurosciences, Inc. $4.14 +2.35% -0.14 $28.92M 0.00%

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

NeuroSense Therapeutics Ltd. is led by CEO Alon Ben-Noon, employs 17 people, headquartered in IL, publicly traded since 2021.

NeuroSense Therapeutics Ltd. (NRSN) stock trades at $0.60 with a market capitalization of $21.21M. The stock is valued at a price-to-earnings (P/E) ratio of -1.35, price-to-book of -9.87, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.58 and $2.09, and currently trades 71.3% below its 52-week high.

On profitability, NeuroSense Therapeutics Ltd. generates a return on equity (ROE) of 543.76% — well above the market average, a sign of a high-quality business, return on capital employed of 744.96%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.neurosense-tx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides